The Landscape of Breast Cancer Molecular and Histologic Subtypes in Canada

To characterize the histologic and molecular subtype distribution of, and survival from, breast cancer (BC) among Canadian women overall, and by stage and age at diagnosis. Invasive BC cases from the Canadian Cancer Registry for women aged 15-99 years between 2012 and 2017 in Canada, excluding Quebe...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2024-09, Vol.31 (9), p.5544-5556
Main Authors: Wilkinson, Anna N, Ellison, Larry F, McGee, Sharon F, Billette, Jean-Michel, Seely, Jean M
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Breast cancer
Breast Neoplasms - pathology
Canada - epidemiology
Female
Forecasts and trends
Gene expression
histology
Humans
Medical screening
Middle Aged
molecular subtype
Neoplasm Staging
net survival
outcomes
Progesterone
stage
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To characterize the histologic and molecular subtype distribution of, and survival from, breast cancer (BC) among Canadian women overall, and by stage and age at diagnosis. Invasive BC cases from the Canadian Cancer Registry for women aged 15-99 years between 2012 and 2017 in Canada, excluding Quebec, were examined using pre-existing mortality linkages. Stage at diagnosis, molecular, and histologic subtypes, and 5-year net survival (NS) by age, subtype, and stage were determined. 107,271 women with BC were included. Luminal A was the most common subtype, present in increasing proportions as women aged, up to a maximum of 55% of cases in 70-74. Ductal and luminal A were most likely to be diagnosed at stage I, while HER2+ had the highest proportion of diagnosis at stage III; triple negative (TN) and unknown had the highest proportion of stage IV. For all stages combined, luminal A had a five-year NS of 98%, while TN was 74%. NS for stage I BC was 99-100% for all subtypes, excepting TN, which was 96%. Survival decreased with advancing stage, most markedly for TN, for which stage III was 47% and stage IV 7%. Survival by equivalent stage and subtype was comparable across age groups but declined in older age categories. The varying natural histories of BC subtypes and histologies can inform prognoses, health system economics, and screening practices. The NS of 96% or greater for stage I, regardless of subtype, highlights the importance of early detection for all subtypes of BC, especially in aggressive subtypes.
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol31090411